ADC Review / Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international, peer-reviewed, online journal covering antibody-drug conjugates, biSpecific antibodies, site-specific antibody-drug conjugates, small-molecule drug conjugates and engineered fragments. We invite you to join our community of over 16,000 professionals in Large Drug Development (Pharma / Biotech), Small & Medium Drug Development, Equipment Manufacturers, Contract Development & Manufacturing Organizations, Regulatory & Government Agencies, Platform Technology and Academia.
ADC Review, Journal of Antibody-drug Conjugates, ADC Directory offers a comprehensive, member driven resource for businesses and professionals alike. Search by solution or service, compare review and connect with fellow members. World ADC attendees, click here to sign up for a FREE Professional Membership today!
MabDesign is a French non-profit membership organization that aims to federate, mobilize and support the development of the industrial sector in the field of immunotherapy.
MabDesign provides strategic leverage and development opportunities for its members, through the creation of a unique directory of stakeholders; by developing specialized training solutions, by providing business development and marketing support; as well as the organisation and support of scientific events, thus promoting networking and innovation.
MabDesign already counts with 160+ members companies, both pharmaceutical and biotechnology industries, service providers, training organizations and equipment suppliers at the front line of technology innovation.
The Antibody Society
The Antibody Society is an international, non-profit representing individuals and organizations involved in antibody-related research and development. The Society’s initiatives and working groups focus on improving the antibody field. We create opportunities for education and networking; monitor and report advances in the commercial pipeline of antibody therapeutics; create standards for characterizing antibody and T-cell receptor repertoires; and engage government and international agencies on matters concerning the antibody community. Please join us!